Cusmedi Co., Ltd. appears in FDA public records as the applicant on a single 510(k) premarket notification, K254222, for a device named PRIMARY (CP.A.B.C.D); PRIMARY (UP.A.B.C.D); PRIMARY-Z (PS.A.B.C.D); PRIMARY-Z (PSS.A.B.C.D); PRIMARY-Z (PSD.A.B.C.D); PRIMARY-O (OR.A.B.C.D); PRIMARY-O (ORS.A.B.C.D); PRIMARY-O (ORD.A.B.C.D). The filing sits in the neurology advisory committee area under product code GXN and regulation 21 CFR 882.5330, described in the record as a preformed, non-alterable cranioplasty plate. The manufacturer's own published pages describe a broader product and technology story, which is separate from what the FDA record establishes. [1][4][7]
The FDA clearance and its scope
The K254222 record lists Cusmedi Co., Ltd. as applicant, with a date received of December 29, 2025 and a decision date of November 6, 2026. The decision code is SESE, described as Substantially Equivalent, and the clearance type is Traditional with no third-party review. The record notes a Summary statement and lists the device class as 2. The filing address in the record is in Suwon-Si, Korea, which is a correspondence address in the filing rather than a verified corporate headquarters. [1]
The device name spans eight model designations grouped under the PRIMARY, PRIMARY-Z and PRIMARY-O prefixes, each followed by a parenthetical code. The openFDA fields classify the device as a Plate, Cranioplasty, Preformed, Non-Alterable, with medical specialty listed as Neurology. The regulation number 882.5330 and product code GXN are consistent across the FDA record and the Innolitics device page. [1][4]
What the manufacturer says it makes
Cusmedi's own website describes the company as specializing in patient-specific implants and states that it combines digital healthcare and medical manufacturing to deliver personalized solutions. The same page presents cranial implant imagery alongside that description. These are the manufacturer's characterizations of its work, published on its site, not findings from the FDA filing. [2]
The company's About page states that Cusmedi was founded in 2015 and develops patient-specific implants using 3D printing and CAD/CAM systems. It lists neurosurgery, orthopedics, plastic surgery, and oral and maxillofacial surgery among the fields it serves. The page also lists a 2025 EN ISO 13485 certification, CE-MDR certification, and regulatory approval in Indonesia, and a 2026 entry citing market entry into Greece and Saudi Arabia. Those items are company-published claims and are not corroborated by the FDA record reviewed here. [7][8]
Portfolio position as of the snapshot
The linked-record collection for this company contains one 510(k) record, and the decision count for that collection is one SESE decision. The record sample likewise contains one entry, K254222, so the sample and the collection coincide at this point in time. These counts describe the filings linked in this snapshot; they are not a measure of total company sales, total product portfolio, or safety performance. [1][3]
An independent aggregator page dated November 17, 2026 likewise lists one 510(k) clearance for Cusmedi Co., Ltd., identifying the November 6, 2026 clearance as the most recent. That page notes its company descriptions may be labeled by a language model while the underlying clearance data come from FDA records. No recall records appear in the linked collection. [3]
Identity and attribution notes
The FDA applicant name is Cusmedi Co., Ltd., and the record's contact is listed as Sejin Oh. No parent company, brand owner, or corporate affiliate is verified in the reviewed sources, so the applicant should be treated as the filing entity itself. The company's published contact page lists an address in Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea, along with telephone, fax, and email details; that is the manufacturer's stated contact information, distinct from the FDA filing address. [1][2]
The product names in K254222 are exact device identities from the FDA record and should be reproduced as filed rather than paraphrased. The Innolitics page reproduces the same record identifier, applicant, product code, decision date, and neurology classification, and places the device under 21 CFR 882.5330 in Subpart F for neurological therapeutic devices. [1][4]

